INTRODUCTION: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease stage. Therefore, we used an inception cohort of RA patients to investigate the association between TRAF1/C5 and cardiovascular mortality, and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may not be restricted to RA, we also studied a large cohort of non-RA patients. METHODS: 615 RA patients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for rs2416808 (R(2) >0.99 with rs10818488). The life/death status was determined and for the deceased persons the cause of death was ascertained. Cox proportional hazards and regression models were used to assess hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Seventy-seven RA patients died. The main death causes in RA patients were cardiovascular diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association was observed between the rs10818488 susceptible genotype AA and cardiovascular mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively). CONCLUSIONS: The TRAF1/C5 region is not associated with an increased mortality risk.
INTRODUCTION: Recently an association between a genetic variation in TRAF1/C5 and mortality from sepsis or cancer was found in rheumatoid arthritis (RA). The most prevalent cause of death, cardiovascular disease, may have been missed in that study, since patients were enrolled at an advanced disease stage. Therefore, we used an inception cohort of RApatients to investigate the association between TRAF1/C5 and cardiovascular mortality, and replicate the findings on all-cause mortality. As TRAF1/C5 associated mortality may not be restricted to RA, we also studied a large cohort of non-RApatients. METHODS: 615 RApatients from the Leiden Early Arthritis Clinic (EAC) (mean follow-up 7.6 years) were genotyped for rs10818488. In addition 5634 persons enrolled in the PROspective Study of Pravastatin in the Elderly at Risk (mean follow-up 3.2 years) were genotyped for rs2416808 (R(2) >0.99 with rs10818488). The life/death status was determined and for the deceased persons the cause of death was ascertained. Cox proportional hazards and regression models were used to assess hazard ratios (HR) and 95% confidence intervals (CI). RESULTS: Seventy-seven RApatients died. The main death causes in RApatients were cardiovascular diseases (37.7%), cancer (28.6%) and death due to infections (9.1%). No association was observed between the rs10818488 susceptible genotype AA and cardiovascular mortality (HR 1.08 95%CI 0.54 to 2.15) and all-cause mortality (HR 0.81 95%CI 0.27 to 2.43). Similar findings were observed for rs2416808 susceptible genotype GG in the non-RA cohort (HR 0.99; 95%CI 0.79 to 1.25 and HR 0.89; 95%CI 0.64 to 1.25, respectively). CONCLUSIONS: The TRAF1/C5 region is not associated with an increased mortality risk.
Authors: Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: J Shepherd; G J Blauw; M B Murphy; S M Cobbe; E L Bollen; B M Buckley; I Ford; J W Jukema; M Hyland; A Gaw; A M Lagaay; I J Perry; P W Macfarlane; A E Meinders; B J Sweeney; C J Packard; R G Westendorp; C Twomey; D J Stott Journal: Am J Cardiol Date: 1999-11-15 Impact factor: 2.778
Authors: Miguel A Gonzalez-Gay; Carlos Gonzalez-Juanatey; Maria J Lopez-Diaz; Angela Piñeiro; Carlos Garcia-Porrua; Jose A Miranda-Filloy; William E R Ollier; Javier Martin; Javier Llorca Journal: Arthritis Rheum Date: 2007-02-15
Authors: D L Mattey; W Thomson; W E R Ollier; M Batley; P G Davies; A K Gough; J Devlin; P Prouse; D W James; P L Williams; J Dixey; J Winfield; N L Cox; G Koduri; A Young Journal: Arthritis Rheum Date: 2007-05
Authors: Fina A S Kurreeman; George N Goulielmos; Behrooz Z Alizadeh; Blanca Rueda; Jeanine Houwing-Duistermaat; Elena Sanchez; Marianna Bevova; Timothy R Radstake; Madelon C Vonk; Emmanouil Galanakis; Norberto Ortego; Willem Verduyn; Maria I Zervou; Bart O Roep; Barbara Dema; Laura Espino; Elena Urcelay; Dimitrios T Boumpas; Leonard H van den Berg; Cisca Wijmenga; Bobby P C Koeleman; Tom W J Huizinga; Rene E M Toes; Javier Martin Journal: Ann Rheum Dis Date: 2009-05-10 Impact factor: 19.103
Authors: Helena Canhão; Ana Maria Rodrigues; Maria José Santos; Diana Carmona-Fernandes; Bruno F Bettencourt; Jing Cui; Fabiana L Rocha; José Canas Silva; Joaquim Polido-Pereira; José Alberto Pereira Silva; José António Costa; Domingos Araujo; Cândida Silva; Helena Santos; Cátia Duarte; Rafael Cáliz; Ileana Filipescu; Fernando Pimentel-Santos; Jaime Branco; Juan Sainz; Robert M Plenge; Daniel H Solomon; Jácome Bruges-Armas; José António P Da Silva; João Eurico Fonseca; Elizabeth W Karlson Journal: Biomed Res Int Date: 2015-03-05 Impact factor: 3.411
Authors: Agnieszka Kempinska-Podhorodecka; Zakera Shums; Michał Wasilewicz; Ewa Wunsch; Malgorzata Milkiewicz; Dimitrios P Bogdanos; Gary L Norman; Piotr Milkiewicz Journal: Clin Dev Immunol Date: 2012-10-22
Authors: Luis Rodríguez-Rodríguez; Raquel López-Mejías; Mercedes García-Bermúdez; Carlos González-Juanatey; Miguel A González-Gay; Javier Martín Journal: Mediators Inflamm Date: 2012-08-02 Impact factor: 4.711